Artelo Biosciences’ oral dual cannabinoid agonist showed weight loss comparable to the GLP-1 receptor agonist semaglutide in obese mice.
When Artelo’s ART27.13 was used in combination with semaglutide, the active ingredient in GLP-1 drugs Ozempic and Wegovy, mice had double the weight loss compared with semaglutide alone. Interestingly, the company reported in a Sept. 16 release that the weight-loss effect was specific to obese mice, as lean mice dosed with ART27.13 alone did not show changes in body weight, fat mass or lean mass.
“The consistency of these results across the initial pilot study and the follow-on study and in every measure we examined—body weight, food consumption, body composition and other metabolic parameters—is what gives us confidence in the signal,” Saoirse O’Sullivan, Ph.D., vice president of translational science at Artelo, said.
The study evaluated ART27.13 alone and in combination with semaglutide in obese mice fed a high-fat diet, as well as ART27.13 alone in lean mice. In obese mice fed a high-fat diet, ART27.13 alone reduced body weight from baseline by approximately 20% over four weeks, similar to the weight loss in mice given semaglutide. Obese mice treated with both ART27.13 and semaglutide lost approximately 40% of their baseline body weight. About 80% of the total weight lost with ART27.13 monotherapy or the combination was fat, compared with about 70% with semaglutide alone.
ART27.13 is an oral cannabinoid receptor agonist that targets cannabinoid receptors 1 and 2, or CB1 and CB2. These two receptors are part of the endocannabinoid system, which helps regulate many functions in the body, including mood, appetite, metabolism and inflammation.
One well-known compound that affects the endocannabinoid system is tetrahydrocannabinol, or THC, the main psychoactive compound in marijuana. THC acts as a partial agonist at cannabinoid receptors, including CB1. ART27.13 is designed to selectively target peripheral CB1 and CB2 receptors, minimizing central nervous system-mediated effects, O’Sullivan explained to Fierce.
Artelo has been developing ART27.13 as a treatment for cancer anorexia-cachexia syndrome, a severe wasting disorder that causes weight loss, muscle wasting and loss of appetite in people with advanced cancer. The asset is currently being evaluated in the phase 2 portion of the CAReS trial, which has operated across five countries, to assess ART27.13's effects on measures including body weight, lean body mass and anorexia.
In September 2025, Artelo announced positive interim phase 2 data showing that patients who reached the highest evaluated dose of ART27.13 gained an average of about 6% of their body weight over 12 weeks, while patients receiving placebo lost about 5%.
Andy Yates, Ph.D., Artelo’s chief scientific officer, told Fierce that Artelo is actively engaging in partnership discussions to best advance ART27.13 for both cancer anorexia-cachexia syndrome and obesity. He sees ART27.13 fitting well into the obesity market alongside GLP-1s while also having a manufacturing advantage, as ART27.13 is a chemically synthesized compound that can be given at very low doses.
“When it comes to my big vision for this drug, I would think of this as a weight management compound,” Yates said.
ART27.13 was originally developed by AstraZeneca under the name AZD1940 for pain. After AstraZeneca discontinued development, rights to the drug were transferred to Montreal-based Neomed Institute, a research center established with $100 million in backing from AstraZeneca, Pfizer and the Quebec government. Artelo entered into an agreement with Neomed in 2017 that gave it an option to exclusively license the drug. Under the deal, Neomed was eligible for milestone payments of up to $202 million, along with royalties on future sales.
Facts Only
* Artelo Biosciences developed ART27.13, an oral dual cannabinoid receptor agonist targeting CB1 and CB2.
* In studies with obese mice on high-fat diets, ART27.13 alone reduced body weight by approximately 20% over four weeks.
* Semaglutide alone produced similar weight loss in obese mice.
* Combined administration of ART27.13 and semaglutide resulted in approximately 40% baseline body weight loss in obese mice.
* 80% of weight loss from ART27.13 monotherapy or combination was fat, compared to 70% for semaglutide alone.
* ART27.13 showed no changes in body weight, fat mass, or lean mass in lean mice.
* The drug is currently in a phase 2 CAReS trial across five countries for cancer anorexia-cachexia syndrome.
* Interim phase 2 data from September 2025 showed patients at the highest dose gained an average of 6% body weight over 12 weeks, while placebo patients lost 5%.
* ART27.13 was originally developed by AstraZeneca as AZD1940 for pain.
* Rights were transferred to Neomed Institute before Artelo entered an exclusive license option agreement in 2017.
* Neomed is eligible for milestone payments up to $202 million and royalties.
Executive Summary
Artelo Biosciences is advancing ART27.13, a chemically synthesized oral compound that targets peripheral CB1 and CB2 receptors. Recent animal studies indicate that ART27.13 achieves weight loss in obese mice comparable to semaglutide, with the two agents acting synergistically to double weight loss when used in combination. Notably, the weight-loss effect appears specific to obese subjects, as lean mice showed no significant change in body composition.
While the compound is being positioned for the obesity market, it is primarily being evaluated in phase 2 human trials for cancer anorexia-cachexia syndrome. Interim data suggests a positive trend in weight gain for patients suffering from cancer-related wasting. The company is currently seeking partnerships to scale development for both indications, citing manufacturing advantages due to the drug's synthetic nature and low required dosage. The asset's transition from an AstraZeneca pain medication to a metabolic regulator highlights a significant shift in its intended therapeutic application.
Full Take
The strongest version of this narrative is that a novel, peripherally selective cannabinoid agonist offers a synergistic partner to GLP-1 drugs, potentially increasing efficacy while maintaining a favorable fat-to-lean mass loss ratio. By avoiding the central nervous system, it aims to provide the metabolic benefits of cannabinoid modulation without the psychoactive effects associated with THC.
However, a critical gap exists between the "signal" in obese mice and the projected success in humans. The narrative relies heavily on the Authority Game, where internal corporate executives present pilot animal data and interim human data—which lacks peer-reviewed methodology or sample sizes—as the primary evidence for a "big vision" of weight management. The transition from treating wasting in cancer patients (adding weight) to treating obesity (losing weight) is a complex pharmacological pivot that is framed here as a seamless expansion.
The underlying paradigm is the "GLP-1 Gold Rush," where any compound showing synergy with semaglutide gains immediate perceived value. This echoes the pattern of repurposing failed or discontinued assets (originally an AstraZeneca pain drug) to fit current market hype. The second-order consequence is the potential for over-promising results based on murine models, which frequently fail to translate to human metabolic outcomes.
Patterns detected: ARC-0043 Authority Game
Who benefits most from this framing? Shareholders and partnership seekers. Who bears the risk? Future patients if the peripheral selectivity does not hold in humans.
Bridge Questions: How does the mechanism for inducing weight gain in cachexia patients differ from the mechanism for inducing weight loss in obese mice? What specific evidence confirms the lack of central nervous system penetration in humans?
Counterstrike Scan: A coordinated campaign would use "scientific" animal data to inflate stock value before a partnership announcement, using the GLP-1 trend as a catalyst. The content matches this pattern moderately, as it emphasizes "synergy" and "market fit" over rigorous clinical data.